

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-97 (cancelled).

98 (currently amended). A compound which is (1) a peptide of not more than having an amino acid sequence of at most 12 amino acid residues from the amino acid sequence of neural cell adhesion molecule (NCAM), or a mimic thereof having an amino acid sequence of at most 12 amino acid residues, wherein said the amino acid sequence of the compound peptide comprises the sequence (K/R)<sub>0-1</sub>-(K/R)-X-(K/R), wherein X is any amino acid, said compound being capable of binding to the NCAM Ig1-Ig2 domains, said peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-4, 9, 12, 14, 15, 17 and 19-22, or and of stimulating or promoting neurite outgrowth from NCAM presenting cells and/or proliferation hereof (2) a compound consisting of four peptide moieties covalently linked to a backbone consisting of three lysines, said peptide moieties each consisting of the same amino acid sequence, said sequence being selected from the group consisting of SEQ ID NOs:1-4, 9, 12, 14, 15, 17 and 19-22,

where said compound is capable of binding to neural cell adhesion molecule (NCAM) or its isolated Ig1 or Ig2 domain.

99-113 (cancelled).

114 (withdrawn, currently amended). A method of treatment of an individual in need of stimulating or promoting neurite outgrowth from NCAM presenting cells and/or proliferation hereof thereof in an individual comprising administering to said individual an effective amount of a compound having at most 12 amino acid residues from the amino acid sequence of neural cell adhesion molecule (NCAM), or a fragment thereof, or a mimic

USSN - 09/787,443

thereof as defined in claim 98 149.

115-118 (cancelled).

119 (withdrawn; currently amended). The method according to claim 114 115, wherein the individual suffers from treatment is for post-operative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuromuscular transmission, and or schizophrenia.

120 (withdrawn; currently amended). The method according to claim 114 115, wherein the individual suffers from a disease treatment is for diseases of muscles, including conditions with impaired function of neuromuscular connections such as genetic or traumatic atrophic muscle disorders.

121 (withdrawn; currently amended). The method according to claim 114 115, wherein the individual suffers from a treatment is for diseases of various organs, such as degenerative conditions condition of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, the liver and or the bowel.

122 (cancelled).

123 (currently amended). A pharmaceutical composition, comprising one or more of the compounds according to claim 149 98.

124-130 (cancelled).

131 (withdrawn). A prosthetic nerve guide, which comprises a pharmaceutical composition according to claim 123.

132-134 (cancelled).

135 (currently amended). The compound according to claim 98 102 having consisting of the sequence ASKKPKRNIKA (SEQ ID NO:1).

USSN - 09/787,443

136 (currently amended). The compound according to claim  
98 having consisting of the sequence AKKERQRKDTQ (SEQ ID NO:2).

137 (currently amended). The compound according to claim  
98 having consisting of the sequence ARALNWGAKPK (SEQ ID NO:3).

138 (currently amended). The compound according to claim  
98 having consisting of the sequence AGSAVKLKKKA (SEQ ID NO: 4).

139 (currently amended). The compound according to claim  
98 having consisting of the sequence ATNKKTGRRRR (SEQ ID NO: 9).

140 (currently amended). The compound according to claim  
98 having consisting of the sequence ARQKTMKPQRS (SEQ ID NO: 12).

141 (currently amended). The compound according to claim  
98 having consisting of the sequence ARKTRERKSKD (SEQ ID NO: 14).

142 (currently amended). The compound according to claim  
98 having consisting of the sequence ASQAKRRRGPR (SEQ ID NO:  
15).

143 (currently amended). The compound according to claim  
98 having consisting of the sequence AKKEKPNKPND (SEQ ID NO: 17).

144 (currently amended). The compound according to claim  
98 having consisting of the sequence AEGGKKKKMRA (SEQ ID NO: 19).

145 (currently amended). The compound according to claim  
98 having consisting of the sequence AKKKEQKQRNA (SEQ ID NO: 20).

146 (currently amended). The compound according to claim  
98 having consisting of the sequence AKSRKGNSSLM (SEQ ID NO: 21).

147 (currently amended). The compound according to claim  
98 having consisting of the sequence ARKS RD MTAIK (SEQ ID NO: 22).

148 (new). The compound of claim 98 which binds the NCAM  
Igl domain.

149 (new). The compound of claim 148 which stimulates or  
promotes neurite outgrowth from NCAM presenting cells and/or  
proliferation thereof.

150 (new). The compound (2) of claim 98, where each peptide  
moiety consists of SEQ ID NO:1.

151 (new). The compound (2) of claim 98, where each peptide

USSN - 09/787,443

moiety consists of SEQ ID NO:2.

152 (new). The compound (2) of claim 98, where each peptide moiety consists of SEQ ID NO:3.

USSN - 09/787,443

Sequence Listing

Please enter the enclosed paper copy Sequence Listing and CRF as replacements for the ones previously filed in this case.